|Awarded On||September 14, 2022|
|Title||Patient-derived Xenograft and Advanced In Vivo Models (PDX-AIM) Core Facility of Texas|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Michael Lewis|
|Cancer Sites||All Sites|
*Pending contract negotiation
With some exceptions, cancer research using tumor-derived cell lines grown on plastic has failed to yield results that benefit patients. To address their shortcomings, researchers have begun to use "patient-derived xenografts" (PDX), in which human tumors are typically grown in immunocompromised mice. Baylor College of Medicine (BCM) and Texas Children's Hospital (TCH) established a Patient-Derived Xenograft and Advanced In Vivo Models (PDX-AIM) Core in 2016 jointly backed by the BCM Advanced Technology Core Laboratories and the Dan L. Duncan Comprehensive Cancer Center. The Core currently provides PDX development, and experimental assistance to 18 PDX Programs, including 16 at BCM/TCH, and ...